4-氨基-5-氯-2,3-二氢N-4-哌啶-7-苯并呋喃甲酰胺

微信扫码

B cell antigen receptor (BCR) signaling pathway is a key driver of tumor growth and spread of many. BTK BCR signal peptide as an indispensable participant in the formation of B lymphocyte differentiation, messaging and is vital for survival. BTK is a signal peptide molecule BCR channel can be identified when the signal peptide molecules across the surface receptors of B lymphocytes, B lymphocytes achieve transport, chemotaxis and adhesion required channel is activated, this is B-cell malignancies forming facilitated.
By Lu BTK inhibitor imatinib is a small molecule can selectively and covalently bound to a cysteine residue (Cys-481) BTK active site, and irreversibly inhibit BTK activity, thereby inhibiting BCR activated signaling pathway, effectively prevent tumor cells to migrate from the B lymphoid tissue suitable for tumor growth, to reduce B cell proliferation and induce apoptosis of malignant cells, which play a role in the treatment of CLL and MCL. Non-clinical studies have shown that by Lu erlotinib can inhibit malignant B lymphocyte proliferation and survival in vivo.